Brokerages Set Dyne Therapeutics, Inc. (NASDAQ:DYN) Target Price at $35.14

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have earned a consensus rating of “Moderate Buy” from the seventeen analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eleven have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $35.1429.

A number of analysts have weighed in on DYN shares. Wall Street Zen cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, December 28th. Robert W. Baird set a $30.00 price objective on Dyne Therapeutics in a report on Monday, December 8th. Sanford C. Bernstein set a $23.00 target price on Dyne Therapeutics in a research report on Tuesday, December 9th. Oppenheimer upgraded Dyne Therapeutics from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $11.00 to $40.00 in a research note on Wednesday, December 10th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a report on Monday, March 9th.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN opened at $17.14 on Wednesday. Dyne Therapeutics has a 52 week low of $6.36 and a 52 week high of $25.00. The company’s 50 day moving average is $17.07 and its two-hundred day moving average is $17.64. The company has a current ratio of 22.25, a quick ratio of 22.25 and a debt-to-equity ratio of 0.15. The company has a market cap of $2.83 billion, a PE ratio of -4.84 and a beta of 1.34.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.02). Equities analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In related news, Director Brian S. Posner acquired 3,000 shares of Dyne Therapeutics stock in a transaction dated Friday, March 6th. The stock was acquired at an average price of $15.06 per share, for a total transaction of $45,180.00. Following the transaction, the director owned 11,500 shares of the company’s stock, valued at $173,190. This represents a 35.29% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Chung Wu Investment Group LLC acquired a new position in Dyne Therapeutics in the third quarter valued at $30,000. Strs Ohio purchased a new position in shares of Dyne Therapeutics during the fourth quarter worth about $51,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Dyne Therapeutics during the fourth quarter worth about $84,000. Steward Partners Investment Advisory LLC increased its position in shares of Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after purchasing an additional 2,465 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Dyne Therapeutics by 25.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock valued at $70,000 after purchasing an additional 1,109 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.